Fabienne Brilot
@FabienneBrilot
Followers
2K
Following
4K
Media
77
Statuses
2K
Neuroimmunologist. Professor @BrainMind_Usyd @Sydney_Uni. Head Brain Autoimmunity Lab, @kids_research, Children's Hospital at Westmead. #iWiMS #ISNI
Sydney, New South Wales
Joined October 2018
2
0
46
"#MOG-IgG serostatus and titre and CSF leucocytosis are #biomarkers of disease course and activity. The findings provide rationale for serial serum MOG-IgG #testing at an interval of 3–6 months in the first 12 months of disease to assist in relapse risk stratification."
Our meta analysis of biomarkers predicting relapse in #MOGAD is out! https://t.co/dm9nhEF6go Relapsing course associated with: ➡️persistent MOG-IgG seropositivity ➡️delayed seroreversion Higher risk of attack associated with: ➡️ higher MOG-IgG titer ➡️CSF leucocytosis @darshi_r
0
2
3
Our meta analysis of biomarkers predicting relapse in #MOGAD is out! https://t.co/dm9nhEF6go Relapsing course associated with: ➡️persistent MOG-IgG seropositivity ➡️delayed seroreversion Higher risk of attack associated with: ➡️ higher MOG-IgG titer ➡️CSF leucocytosis @darshi_r
3
12
30
Amazing to see #iWiMS @AnneProbstel and Veronique Miron on stage receiving the #ISNI awards. Congrats! Our secretary @FabienneBrilot was there too!
Congratulations to @AnneProbstel Veronique Miron & Qiang Liu, the 3 #ISNI #WeAreNeuroimmunology Mid-Career Awardees! Fantastic talks at #ISNI2025 and bright future in neuroimmunological research. 🎉 @hwiendl @FabienneBrilot
0
2
8
Congratulations to @AnneProbstel Veronique Miron & Qiang Liu, the 3 #ISNI #WeAreNeuroimmunology Mid-Career Awardees! Fantastic talks at #ISNI2025 and bright future in neuroimmunological research. 🎉 @hwiendl @FabienneBrilot
1
2
18
Can’t wait! The program looks awesome. Japan looks awesome. Awesomeness all around. #WeAreNeuroimmunology.
Are you ready for #ISNI2025? Join @hwiendl @QuintanaLabHMS @jonykipnis @LatorreDanielaa @AkassoglouLab @Britta_in_Bern for a program packed full of great #neuroimmunology updates. See you in beautiful Japan!#WeAreNeuroimmunology. https://t.co/ZzhfH93eNQ
0
1
8
Discussing current and emerging treatments in #NMOSD and #MOGAD. Great talk by @darshi_r at #ECTRIMS2025. @TheMOGProject @TheSumairaFDN
0
4
18
Check out our STAR-MOG investigator led phase III RCT in MOGAD presented by @IzzyCotter at the @ECTRIMS poster session today! @syd_health @TheMOGProject @MS_Australia @TheSumairaFDN
1
6
20
"...live CBAs can be validated in diagnostic laboratories across range of flow #cytometers with high reproducibility & repeatability. In particular, excellent assay performance on spectral flow #cytometry strongly supports proof-of-concept use...for diagnostic purposes." #MOGAD
Good news story for #MOGAD ➡️ High concordance in flow live MOG-IgG testing between conventional/full spectrum, research/diagnostic flow cytometers ➡️ Flow live CBA can be validated for diagnostic purposes @darshi_r @syd_health @BrainMind_Usyd
https://t.co/Wasen4VkF9
0
3
6
At #ECTRIMS2025? Join the #iWiMS reception to hear from our international panel @darshi_r @EthelScl Noriko Isobe JackiePalace Antje Bischof Malya Sahu & Sibongile Tito, and welcome @KristenKryskoMD, #RachelHornePrize winner 2025! Hilton Diagonal Mar Ballroom A1+A2 at 6:30pm
0
5
9
Good news story for #MOGAD ➡️ High concordance in flow live MOG-IgG testing between conventional/full spectrum, research/diagnostic flow cytometers ➡️ Flow live CBA can be validated for diagnostic purposes @darshi_r @syd_health @BrainMind_Usyd
https://t.co/Wasen4VkF9
0
9
21
Thank you to @MS_Australia for this great piece. ➡️ COVID-19 VAX boosters improve the longevity and cross-variant breadth of immune responses in #MS ➡️ machine-learning models predict protection or need of an extra booster. @anneke_vdw @darshi_r @StuartTurville @syd_health
A new Australian study shows COVID-19 boosters improve protection against new variants for people with #MS, even when taking immune-suppressing treatments. Read more 👇
0
4
10
It’s been a privilege to exchange knowledge on multiple sclerosis with our #Australian colleagues Jeannette Lechner-Scott, Anneke van der Walt, Tomas Kalincik & others. Thank you for visiting our centre — we truly valued the collaboration! @ECTRIMS @cemcat_em @vallhebron @VHIR_
1
8
25
👏🏆Congrats to @KristenKryskoMD 2025 winner of the #RachelHornePrize for Women's Research in MS for her outstanding work on how best to guide/treat women with #MS during pregnancy & breastfeeding! @UnityHealthTO,@SMHNeurology,@UofTNeurology Tx to @ECTRIMS,@ACTRIMS,@IntNatlWiMS
7
23
89
The 1-month countdown for @ECTRIMS Patient Community Day 2025 in Barcelona has begun! 🇪🇸 ECTRIMS Patient Community Day is the largest coming together of patients living with #MOGAD, #MS, #NMOSD and related neurological diseases. Register: https://t.co/5H7RCE0Gow
0
4
12
New review from Carson Moseley and @ZamvilScott on B cell antigen presentation in CNS autoimmunity https://t.co/YLEkaSnTdn
0
3
10
Hot of the press today, check out our neuro AT now PhD student Dr Hannah Ford's paper below - highlighting the importance of clinical acumen in ordering autoantibody tests. Well done Hannah👏👏 @MonashSTM
https://t.co/Dz4Jjtm5kM
onlinelibrary.wiley.com
This single center retrospective study analyzed testing indications and yield of neuronal cell-surface antigen antibody (NCSAA) and intracellular neuronal antigen antibody (INAA) testing for autoim...
1
1
12
Can you take b-cell depleters like ocrevus, kesimpta, and rituximab less often? According to this meta analysis of 19 studies on the topic, YES! "Extended interval dosing does not increase the risk of relapse, MRI activity, disability progression."
msard-journal.com
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system (CNS), affecting approximately 2.8 million individuals worldwide (Walton et al., 2020). Among...
2
19
63
In our recent study, the "Insular Knife Cut" Sign had 99.3% specificity for HSV encephalitis and was often detectable early after symptoms onset on brain MRI. An ominous sign not to miss in patients with suspected encephalitis of new onset!!! https://t.co/l6jrmxHeHV
4
68
188
Current routinely used assessments such as high contrast visual acuity underestimate residual visual dysfunction in MOG-ON. There is a need for prospective studies evaluating the prognostic value of low contrast visual acuity, contrast sensitivity, and OCT/OCT-A on visual QoL.
1
2
3